S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:RGLS

Regulus Therapeutics News Headlines

$0.23
+0.02 (+9.70%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.20
$0.24
50-Day Range
$0.16
$0.34
52-Week Range
$0.16
$1.48
Volume
1.44 million shs
Average Volume
4.26 million shs
Market Capitalization
$33.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.21
Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Regulus Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGLS
News Sentiment

0.45

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGLS Articles
This Week

2

1

RGLS Articles
Average Week



Regulus Therapeutics (NASDAQ:RGLS) News Headlines Today

SourceHeadline
MarketBeat logoRegulus Therapeutics (NASDAQ:RGLS) Lifted to "Buy" at Zacks Investment Research
americanbankingnews.com - May 16 at 3:20 AM
MarketBeat logoRegulus Therapeutics (NASDAQ:RGLS) Receives Overweight Rating from Cantor Fitzgerald
americanbankingnews.com - May 13 at 3:26 AM
seekingalpha.com logoRegulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 3:18 AM
finance.yahoo.com logoRegulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
finance.yahoo.com - May 13 at 3:18 AM
MarketBeat logoRegulus Therapeutics Inc. (NASDAQ:RGLS) to Post FY2022 Earnings of ($0.25) Per Share, Cantor Fitzgerald Forecasts
americanbankingnews.com - May 13 at 2:50 AM
MarketBeat logoStockNews.com Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS)
americanbankingnews.com - May 13 at 1:30 AM
finance.yahoo.com logoRegulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
finance.yahoo.com - May 12 at 2:31 PM
seekingalpha.com logoRegulus spikes as FDA clears trial for kidney disease candidate
seekingalpha.com - May 11 at 2:38 PM
benzinga.com logoFDA Clears Regulus Therapeutics' IND for RGLS8429 In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
benzinga.com - May 11 at 9:38 AM
finance.yahoo.com logoRegulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
finance.yahoo.com - May 11 at 9:38 AM
MarketBeat logoRegulus Therapeutics (RGLS) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - May 10 at 4:42 AM
finance.yahoo.com logoRegulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call
finance.yahoo.com - May 5 at 8:59 PM
MarketBeat logoRegulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com
americanbankingnews.com - May 5 at 1:44 AM
finance.yahoo.com logoRegulus Therapeutics Inc. (RGLS)
finance.yahoo.com - May 3 at 8:26 PM
seekingalpha.com logoRGLS Regulus Therapeutics Inc.
seekingalpha.com - April 30 at 6:53 PM
finance.yahoo.com logoRegulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital
finance.yahoo.com - March 24 at 8:38 PM
finance.yahoo.com logoRegulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital
finance.yahoo.com - March 24 at 10:33 AM
seekingalpha.com logoRegulus Therapeutics GAAP EPS of -$0.07
seekingalpha.com - March 12 at 10:00 PM
finance.yahoo.com logoRegulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates
finance.yahoo.com - March 10 at 6:13 PM
seekingalpha.com logoRegulus Therapeutics Q4 2021 Earnings Preview
seekingalpha.com - March 9 at 9:43 PM
benzinga.com logoRegulus Therapeutics's Earnings: A Preview
benzinga.com - March 9 at 4:06 PM
finance.yahoo.com logoRegulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
finance.yahoo.com - February 24 at 1:09 PM
finance.yahoo.com logoRegulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 5:13 PM
finance.yahoo.com logoRegulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
finance.yahoo.com - January 26 at 1:44 PM
finance.yahoo.com logoRegulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder
finance.yahoo.com - January 21 at 12:18 PM
marketwatch.com logoRegulus Therapeutics Says FDA Meeting Successful, Shares Rise 6%
marketwatch.com - January 20 at 6:32 PM
finance.yahoo.com logoRegulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429
finance.yahoo.com - January 20 at 6:32 PM
finance.yahoo.com logoRegulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development
finance.yahoo.com - December 3 at 9:56 AM
finance.yahoo.com logoRegulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit
finance.yahoo.com - December 1 at 9:46 AM
finance.yahoo.com logoRegulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity
finance.yahoo.com - November 30 at 6:55 PM
finance.yahoo.com logoRegulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 10 at 11:07 PM
finance.yahoo.com logoRegulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates
finance.yahoo.com - November 10 at 6:07 PM
finance.yahoo.com logoRegulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call
finance.yahoo.com - November 3 at 8:24 PM
finance.yahoo.com logoAnalysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - October 28 at 9:05 PM
msn.com logoHow The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More
msn.com - October 18 at 9:53 PM
benzinga.com logoRegulus Therapeutics Reports Strategic Prioritization Of RGLS8429 Candidate For Treatment Of Autosomal Dominant Polycystic Kidney Disease
benzinga.com - October 14 at 1:24 AM
marketwatch.com logoRegulus Therapeutics to Prioritize RGLS8429 Treatment for Certain Kidney Disease
marketwatch.com - October 14 at 1:24 AM
msn.com logoBRIEF-Regulus Therapeutics Announces Strategic Prioritization Of Polycystic Kidney Disease Treatment
msn.com - October 12 at 6:19 PM
finance.yahoo.com logoRegulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease
finance.yahoo.com - October 12 at 6:19 PM
finance.yahoo.com logoRegulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science
finance.yahoo.com - September 30 at 6:58 PM
finance.yahoo.com logoRegulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 6:23 PM
benzinga.com logoRecap: Regulus Therapeutics Q2 Earnings
benzinga.com - August 12 at 10:58 PM
finance.yahoo.com logoRegulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 10 at 11:11 PM
finance.yahoo.com logoRegulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call
finance.yahoo.com - August 3 at 8:16 PM
nasdaq.com logoRegulus Therapeutics Inc. Common Stock (RGLS)
nasdaq.com - July 24 at 9:43 PM
finance.yahoo.com logoIs Regulus Therapeutics Inc (RGLS) A Good Stock To Buy?
finance.yahoo.com - June 30 at 1:36 PM
finance.yahoo.com logoRegulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
finance.yahoo.com - June 25 at 8:08 AM
finance.yahoo.com logoRegulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
finance.yahoo.com - June 21 at 8:27 AM
finance.yahoo.com logoDo Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?
finance.yahoo.com - June 11 at 9:43 AM
nasdaq.com logoIs Regulus Therapeutics (NASDAQ:RGLS) Using Too Much Debt?
nasdaq.com - June 9 at 2:20 PM
Get Regulus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.